146 results on '"Kawano, Mahiru"'
Search Results
2. Cervical Cancer: General Overview
3. Management of Early-Stage and Locally Advanced Cervical Cancer
4. Abstract B059: A patient-derived xenograft (PDX) orthotopic mouse model of rare gynecologic mesonephric-like adenocarcinoma as a platform of personalized medicine
5. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer
6. Prognostic significance of bone marrow FDG uptake in patients with gynecological cancer
7. Lupus-like autoimmune disease caused by a lack of Xkr8, a caspase-dependent phospholipid scramblase
8. Management of Metastatic and Recurrent Cervical Cancer
9. Cervical Cancer: General Overview
10. Management of Early-Stage and Locally Advanced Cervical Cancer
11. Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer
12. Pretreatment tumor-related leukocytosis misleads positron emission tomography-computed tomography during lymph node staging in gynecological malignancies
13. Supplementary Figure 1 from Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary
14. Data from Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary
15. Supplementary Table 1 and 2 from Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary
16. Pre-treatment prognostic nutritional index is superior to platelet count in predicting disease-specific survival in patients with epithelial ovarian cancer
17. Prognostic significance of systemic neutrophil and leukocyte alterations in surgically treated endometrial cancer patients: A monoinstitutional study
18. The significance of lymphatic space invasion and its association with vascular endothelial growth factor-C expression in ovarian cancer
19. Impact of histological subtype on survival of patients with surgically-treated stage IA2–IIB cervical cancer: Adenocarcinoma versus squamous cell carcinoma
20. Targeting mTOR Signaling in Ovarian Cancer
21. Endometrial galectin‐3 causes endometriosis by supporting eutopic endometrial cell survival and engraftment in the peritoneal cavity
22. Cervical Cancer: General Overview
23. Management of Early-Stage and Locally Advanced Cervical Cancer
24. Management of Metastatic and Recurrent Cervical Cancer
25. First two cases of primary carcinoma of the vagina successfully treated with concurrent weekly carboplatin plus paclitaxel, external beam radiotherapy and high-dose-rate interstitial brachytherapy: A case report and published work review
26. Uterine Cervical Cancer Displaying Tumor-Related Leukocytosis: A Distinct Clinical Entity With Radioresistant Feature
27. Significance of Pretreatment C-Reactive Protein, Albumin, and C-Reactive Protein to Albumin Ratio in Predicting Poor Prognosis in Epithelial Ovarian Cancer Patients
28. Exploring the potential of engineered exosomes as delivery systems for tumor-suppressor microRNA replacement therapy in ovarian cancer
29. Significance of Pretreatment C-Reactive Protein, Albumin, and C-Reactive Protein to Albumin Ratio in Predicting Poor Prognosis in Epithelial Ovarian Cancer Patients.
30. The role of myeloid-derived suppressor cells in endometrial cancer displaying systemic inflammatory response: clinical and preclinical investigations
31. Direct oral anticoagulants are effective and safe for the treatment of venous thromboembolism associated with gynecological cancers
32. Abstract 2585: The development of a novel microRNA replacement therapy for ovarian cancer - a potential of patient derived-exosomes as a carrier
33. Prognostic significance of the pretreatment prognostic nutritional index in patients with epithelial ovarian cancer
34. Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models
35. Postoperative inflammatory response after laparoscopic radical hysterectomy in patients with early-stage cervical cancer
36. Prostaglandin E2 produced by myeloid-derived suppressive cells induces cancer stem cells in uterine cervical cancer
37. Chronic pelvic pain due to pelvic lymphangioleiomyomatosis: A case report
38. Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer
39. Efferocytosis and autoimmune disease
40. The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations
41. PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo
42. Comparison of clinical utilities of the platelet count and platelet-lymphocyte ratio for predicting survival in patients with cervical cancer: a single institutional study and literature review
43. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary
44. The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer
45. Prognostic Significance of Pretreatment Thrombocytosis in Cervical Cancer Patients Treated With Definitive Radiotherapy
46. Abstract 1642: Antitumor activity of lurbinectedin toward ovarian clear cell carcinoma
47. Clinical implication of surgically treated early-stage cervical cancer with multiple high-risk factors
48. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary
49. Ovarian insufficiency following allogeneic hematopoietic stem cell transplantation.
50. Abstract 1103: MDSC targeting therapy for uterine cervical cancer displaying TRL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.